Insights

Niche market focus REMED operates in regenerative medicine research services with a small to mid-sized team, suggesting opportunities to provide specialized R&D tooling, data services, or regulatory support tailored to niche biotech clients seeking to translate therapies from bench to clinic.

Limited revenue base Current revenue is in the zero to one million range, indicating potential for growth through partnerships, contract research, and service packages that scale with project complexity typical in early-stage regenerative medicine programs.

Digital engagement Presence on multiple social and web platforms (LinkedIn, Facebook, Google tools) implies receptiveness to outreach via content marketing, webinars, and targeted digital campaigns to raise awareness among researchers and potential collaborators.

Competitive landscape Similar peers range from niche rehabilitation centers to larger neuroscience and recovery institutions, presenting opportunities to differentiate through specialized regenerative medicine capabilities, clinical translation support, and collaboration on grant-funded projects.

Talent and capacity Employee count (51-200) positions REMED to engage with mid-size project teams; sales prospects could include scalable service bundles, training programs, and co-development arrangements that align with their project throughput and growth plans.

Similar companies to REMED

REMED Tech Stack

REMED uses 8 technology products and services including gstatic.com, LinkedIn, PHP, and more. Explore REMED's tech stack below.

gstatic.com
Content Delivery Network
LinkedIn
Online Community Software
PHP
Programming Languages
WhatsApp
Social Sharing
Animate.css
UI Frameworks
Google Search Console
Web Analytics
jQuery Waypoints
Web Tools And Plugins
Facebook
Widgets

REMED's Email Address Formats

REMED uses at least 2 format(s):

REMED Email Formats	Example	Percentage
FLast@remed.com	JDoe@remed.com	91%
First.Last@remed.com	John.Doe@remed.com	8%
LastF@remed.com	DoeJ@remed.com	1%
First.Last@tums.ac.ir	John.Doe@tums.ac.ir	94%
FirstLast@tums.ac.ir	JohnDoe@tums.ac.ir	5%
FLast@tums.ac.ir	JDoe@tums.ac.ir	1%

Frequently Asked Questions

What is REMED's stock symbol?

REMED is a publicly traded company; the company's stock symbol is REMEDY.HE.

What is REMED's official website and social media links?

REMED's official website is tums.ac.ir and has social profiles on LinkedIn.

How much revenue does REMED generate?

As of July 2026, REMED's annual revenue is estimated to be <$1M.

What is REMED's NAICS code?

REMED's NAICS code is 5417 - Scientific Research and Development Services.

How many employees does REMED have currently?

As of July 2026, REMED has approximately 55 employees across 5 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer: C. R.Chief Information Officer: M. H.Vice President Of Operations: E. S.. Explore REMED's employee directory with LeadIQ.

What industry does REMED belong to?

REMED operates in the Research Services industry.

What technology does REMED use?

REMED's tech stack includes gstatic.comLinkedInPHPWhatsAppAnimate.cssGoogle Search ConsolejQuery WaypointsFacebook.

What is REMED's email format?

REMED's email format typically follows the pattern of FLast@remed.com. Find more REMED email formats with LeadIQ.

When was REMED founded?

REMED was founded in 2020.

REMED

Q: What is REMED's official website and social media links?

REMED's official website is tums.ac.ir. REMED has social profiles on LinkedIn.

Q: How many employees does REMED have currently?

REMED has approximately 55 employees.

Q: What industry does REMED belong to?

REMED operates in the Research Services industry.

Q: What technology does REMED use?

REMED's tech stack includes Google Tag Manager, Google Maps, X-UA-Compatible, LinkedIn, Nginx.

Q: What is REMED's NAICS code?

REMED's NAICS code is 5417 (Scientific Research and Development Services).

Research ServicesTehrān, Iran51-200 Employees

REMED is a Tehran-based research services company focused on regenerative medicine, an area aiming to restore normal function to cells, tissues, or organs harmed by disease or injury. Its work centers on turning promising laboratory findings into clinical applications, reflecting a growing emphasis on translating research from the lab to patient care. The organization operates with a mid-sized team that supports its translational science activities. Its customers include researchers, healthcare institutions, and clinicians seeking regenerative treatment options. By bridging fundamental research and patient-ready therapies, REMED addresses the practical challenge of moving scientific discoveries into usable medical interventions. Located in Tehran, Iran, the company sits within the broader regenerative medicine landscape that prioritizes clinical translation.